36 results
8-K
EX-99.1
RNAC
Cartesian Therapeutics Inc
7 Mar 24
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7:06am
are making strong progress in our mission to deliver innovative cell therapies to patients suffering from autoimmune diseases,” said Carsten Brunn, Ph.D
8-K
EX-99.1
RNAC
Cartesian Therapeutics Inc
5 Mar 24
Entry into a Material Definitive Agreement
7:05am
has clinical and commercial manufacturing scale capabilities designed to support the Company's maturing pipeline of innovative mRNA cell therapies
8-K
EX-99.3
ddx4gt
8 Jan 24
Regulation FD Disclosure
8:45am
8-K
EX-99.2
lwq tbusp1rf
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
DEFR14A
4lnyg3nf1mu vquugs
3 May 22
Revised proxy
2:15pm
PRE 14A
gh683hcitb1m5o
22 Apr 22
Preliminary proxy
3:08pm
8-K
EX-99.1
7so7x
9 Nov 21
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
lub115aac5sbv c51k5
12 Aug 21
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
9:04am